Purchase this article with an account.
Rie Ofusa, Yoshimi Sugiura, Fumiki Okamoto, Yoshifumi Okamoto, Tetsuro Oshika; Visual Function in Patients with Type 1 Idiopathic Macular Telangiectasia. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1166.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate visual function in patients with type 1 idiopathic macular telangiectasia (MacTel), and to determine the effect of intravitreal bevacizumab on visual function.
Seventeen eyes of 17 patients with type 1 MacTel and 18 age-matched normal controls were included. All patients were examined for the logarithm of the minimal angle of resolution best-corrected visual acuity (log MAR BCVA), contrast sensitivity with CSV-1000E, severity of metamorphopsia with the M-CHARTS, amount of aniseikonia with the New Aniseikonia Test, and stereopsis with the Titmus stereo test (TST) and the TNO stereotest. From the data obtained with CSV-1000E, the area under the log contrast sensitivity function (AULCSF) was calculated.
The mean log MAR BCVA was 0.22 (range: -0.08 - 1.00), and mean AULCSF was 1.03 (range: 0.61 - 1.46) in patients with type 1 MacTel. Visual acuity and contrast sensitivity in patients with type 1 MacTel were significantly worse than those in normal controls (p < 0.005 and p < 0.0005, respectively). Metamorphopsia was observed in 15 of 17 eyes, and the mean metamorphopsia score was 0.49. All eyes had micropsia, and the mean amount of aniseikonia was 2.7%. Stereopsis in TST and TNO stereotests was significantly worse in patients with type 1 MacTel than in normal controls (p < 0.005 and p < 0.05, respectively). Seven of 17 eyes were treated with intravitreal bevacizumab. Visual acuity improved in 6 of the 7 eyes, while contrast sensitivity and aniseikonia improved in 5 of the 7 eyes one month after treatment. Metamorphopsia improved in 4 of the 7 eyes, and their stereopsis did not change.
These results suggested that not only visual acuity, but also contrast sensitivity, metamorphopsia, aniseikonia, and stereopsis deteriorated in patients with type 1 MacTel. Intravitreal bevacizumab treatment improved most visual functions except for stereopsis.
This PDF is available to Subscribers Only